cells through the expression of single transcription factors, 5, 6 but the recipe for activation of the cardiac muscle program had remained elusive.
If Srivastava's approach of inducing cardiac myocytes could be used clinically, not only might it minimize cancer risk, but also it might eliminate engraftment problems too, because instead of introducing new cells, cardiologists could potentially change the fibroblasts of the scar itself.
On face value, Srivastava's results sound very exciting. The story received a good deal of press coverage, and scientists have described the report as "a wonderful study," "impressive," and "fascinating." However, for some of those scientists, the praise comes with a dose of common sense, caution, and even a hint of disbelief.
"I think that it's potentially a significant advance. What remains to be determined is how efficient this process is, how straightforward it is to replicate, and whether it requires specialized conditions," says Eric Olson, Professor and Chairman of Molecular Biology, University of Texas Southwestern, Dallas, Tex. "It is so important and so provocative that it is absolutely essential that it be reproduced. And not just reproduced, but reproduced easily," says Ken Chien, the Sanders Professor in the Department of Stem Cell and Regenerative Biology at Harvard University, Boston, Mass. Summing up what seems to be the general mood among scientists in the field, Schwartz adds, "It's an astounding observation, and many of us researchers would love to test it and see if this really works."
A number of groups have been attempting to replicate the results of the article but have had little success, yet. But Srivastava is not worried: "I think it is healthy for the field to have skepticism about any such result that is somewhat transformative," he says, "but time will show."
He is sending his reagents to researchers who have asked for them, and now, it is a matter of waiting, he says. "They'll get it to work because we've had many people in my lab who can make it work. . . the key to it is getting high enough levels of expression of the reprogramming factors. You need to have high-titer vectors that will infect the cells."
Assuming Srivastava is right, that robust replication of the procedure is possible, there will be many steps to optimize and modify before there is any hope of using such a technique in the clinic. One issue is the efficiency of the transdifferentiation, says Olson. Srivastava and colleagues report that following transfection with the three factors, 20% of fibroblasts were induced to express ␣MHC-a marker of cardiac myocytes-but only 30% of that 20% went on to express cardiac troponin-a marker of the sarcomere structure of cardiac myocytes-and only 30% of that 30% exhibited spontaneous contraction. That works out to just 1.8% of the starting cell population that achieved the intended phenotype.
Another question is the maturity of the induced cells. Although this 1.8% of cells displayed contractile ability, whether this ability equates to the full contractile force of an adult cardiac myocyte is unknown. Also unknown is whether the cells are capable of electrically coupling to the existing heart cells in vivo.
The results presented in the current article are based on transfections performed on neonatal mouse fibroblasts in vitro. "We have tried adult fibroblasts, as well," says Srivastava, "and they work." But the two big questions are, will it work in human cells, and can fibroblasts of the heart be transdifferentiated directly in vivo, says Shinya Yamanaka, also at the Gladstone Institute of Cardiovascular Disease. "We really want to make it happen in patients, not Petri dishes," Yamanaka says.
As it turns out, the issue of in vivo transdifferentiation might be among the easier hurdles to overcome: "We have data from our own lab that suggests you can do the reprogramming in vivo relatively more efficiently than in vitro," says Olson, "It may be because the microenvironment is more conducive to this type of reprogramming or it might be that prolonged proliferation or maintenance of fibroblasts in tissue culture may impede the reprogramming process."
If reprogramming the cells directly in vivo becomes a possibility, to make the switch from experimental organism to human would likely require a different factor delivery system, such as small molecules or protein transduction, neither of which are optimized. The retrovirus vector that Srivastava and colleagues used in their study integrates into the cell's genome and, thus, can potentially cause dangerous mutations.
"The game changer is being able to do it in vivo," says Chien, but points out that even if all the issues of efficiency, functionality, and safe delivery are overcome, scientists would still have to figure out how to restrict the transdifferentiation to fibroblasts: "If you hit vascular cells, nerve cells, or pacemaker cells and start converting them to ventricular muscle, that would be a mess."
It is not clear whether the same three factors would be able to convert other cell types into cardiac myocytes. iPS cells can be derived from fibroblasts, 4 liver cells, stomach cells, 7 and blood 8 using the same four factors. Thus, if Gata4, Mef2c, and Tbx5 do turn out to be master regulators of cardiomyogenesis, the challenge will be not only to boost their power in target fibroblasts, but also to prevent their power elsewhere.
As with any paradigm-shifting study, there are many ifs, buts, and maybes between Srivastava's proof-of-principle article and the clinic. The first and most important if, is whether researchers can validate the findings through replication. From that point, it will hopefully just be a matter of refining the recipe. 
